Juniper Pharmaceuticals (NASDAQ: JNP) and Parnell Pharmaceuticals Holdings (NASDAQ:PARN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitabiliy.


This table compares Juniper Pharmaceuticals and Parnell Pharmaceuticals Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 12.00% 19.03% 12.65%
Parnell Pharmaceuticals Holdings -130.46% -83.86% -43.24%

Institutional & Insider Ownership

34.3% of Juniper Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Parnell Pharmaceuticals Holdings shares are held by institutional investors. 7.2% of Juniper Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Juniper Pharmaceuticals and Parnell Pharmaceuticals Holdings’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Juniper Pharmaceuticals $55.34 million 1.02 $7.46 million $0.61 8.52
Parnell Pharmaceuticals Holdings N/A N/A N/A N/A N/A

Juniper Pharmaceuticals has higher revenue and earnings than Parnell Pharmaceuticals Holdings.

Risk & Volatility

Juniper Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Parnell Pharmaceuticals Holdings has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Juniper Pharmaceuticals and Parnell Pharmaceuticals Holdings, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 2 1 0 2.33
Parnell Pharmaceuticals Holdings 0 0 0 0 N/A

Juniper Pharmaceuticals currently has a consensus price target of $9.38, indicating a potential upside of 80.29%. Given Juniper Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Juniper Pharmaceuticals is more favorable than Parnell Pharmaceuticals Holdings.


Juniper Pharmaceuticals beats Parnell Pharmaceuticals Holdings on 9 of the 9 factors compared between the two stocks.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.

Parnell Pharmaceuticals Holdings Company Profile

Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.